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A B S T R A C T
Purpose
Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite
prospective study TBCRC 005was conducted to examine the ability of a novel panel of cell-free DNA
methylation markers to predict survival outcomes in metastatic breast cancer (MBC) using a new
quantitative multiplex assay (cMethDNA).
Patients and Methods
Ten genes were tested in duplicate serum samples from 141 women at baseline, at week 4, and at
first restaging. A cumulative methylation index (CMI) was generated on the basis of six of the
10 genes tested. Methylation cut points were selected to maximize the log-rank statistic, and cross-
validation was used to obtain unbiased point estimates. Logistic regression or Cox proportional
hazard models were used to test associations between the CMI and progression-free survival (PFS),
overall survival (OS), and disease status at first restaging. The added value of the CMI in predicting
survival outcomes was evaluated and compared with circulating tumor cells (CellSearch).
Results
Median PFS and OS were significantly shorter in women with a high CMI (PFS, 2.1 months; OS,
12.3months) versus a low CMI (PFS, 5.8months; OS, 21.7months). Inmultivariablemodels, among
women with MBC, a high versus low CMI at week 4 was independently associated with worse PFS
(hazard ratio, 1.79; 95% CI, 1.23 to 2.60; P = .002) and OS (hazard ratio, 1.75; 95% CI, 1.21 to 2.54;
P = .003). An increase in the CMI from baseline to week 4was associatedwith worse PFS (P, .001)
and progressive disease at first restaging (P , .001). Week 4 CMI was a strong predictor of PFS,
even in the presence of circulating tumor cells (P = .004).
Conclusion
Methylation of this gene panel is a strong predictor of survival outcomes in MBC and may have
clinical usefulness in risk stratification and disease monitoring.
J Clin Oncol 35:751-758. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Significant therapeutic advances in the field of
breast cancer have resulted in a growing number
of treatment options for patients with metastatic
breast cancer (MBC), and prioritization of these
agents can be challenging. In practice, many
months are often needed to determine whether
the selected treatment is effective, a decision usually
guided by clinical findings and imaging studies.
The identification of highly accurate circulating
molecular markers in blood that allows earlier
evaluation of therapeutic benefit could help sig-
nificantly in clinical decision making, minimize
morbidity from ineffective therapy, reduce costs
from additional imaging studies, and improve
clinical outcomes.1,2 The current generation of
circulating markers offers some prognostic use-
fulness but these are not predictive for clinical
benefit from individual therapies.3
Epigenetic alterations are among the most
common molecular abnormalities in human
cancers.4 DNA methylation does not change the
genomic DNA sequence and is a form of epi-
genetic alteration that is heritable during DNA
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replication.5,6 Tumors commonly release aberrant DNA into the
bloodstream, and this can now be detected. Our group devel-
oped a highly sensitive high-throughput quantitative multiplex
methylation-specific polymerase chain reaction assay named
cMethDNA to detect circulating cell-free methylated DNA.7 This
assay builds on the prior assays we had used to detect methylation in
tissue and in cytologic samples.8-11 A few clinical studies have since
examined the association between the presence or absence of cell-
free methylated DNA in peripheral blood and disease outcomes, but
none have quantified the level of methylation.7,12-15 TBCRC 005 is
the first biomarker study designed specifically to prospectively test as
a primary end point the role of DNA methylation in blood in
predicting disease progression and survival in breast cancer.
PATIENTS AND METHODS
Study Design
Eligible participants included female patients $ 18 years of age with
histologically confirmed MBC and measurable disease and an Eastern
Cooperative Oncology Group performance status of 0 to 2, who were
starting a new systemic therapy and being treated at one of seven par-
ticipating US academic medical centers. Measurable/evaluable disease was
defined as a lesion $ 1 cm on computed tomography scan or magnetic
resonance imaging or a superficial/palpable lesion $ 2 cm. Patients with
a diagnosis of a second cancer in the previous 5 years were excluded, with the
exception of those womenwith basal or squamous cell carcinoma of the skin
and/or cervical carcinoma in situ. All patients provided written informed
consent. The institutional review board at each study site approved this study.
The study schema is outlined in Appendix Figure A1 (online only).
Blood was collected at baseline, at week 4, and at first restaging (which was
at the discretion of the treating oncologist). At all three time points, serum
samples were processed locally and stored at 280°C within 4 hours of
collection. The samples were then batched and shipped to Johns Hopkins,
where they were stored at 280°C. Whole blood for analysis of circulating
tumor cells (CTCs) was collected at baseline and at week 4 and was sent to
the Clinical Laboratory Improvement Amendments–certified Clinical
Chemistry Research Laboratory at Johns Hopkins for processing within
72 hours of collection.
Methylation and CTC Assays
The cMethDNA assay was used to measure duplicate samples of
a methylation panel from a previously published 10-gene panel in 300 mL of
serum.7,16 In addition, a set of identical quality control pooled specimens
from approximately 5% of the total samples was inserted into every batch to
assess inter- and intrabatch reproducibility. All samples from one individual
were run in the same batch to minimize bias from interassay variability.
Individual genemethylation (M) was calculated as amethylation index (MI):
MI ¼ No: methylated copies
No: methylated þ gene standard copies ð100Þ
The MI of each sample was averaged across duplicates. The cumulative
methylation index (CMI) is the sum of theMI for all genes. CTCs in 7.5 mL
of whole blood were isolated and enumerated on the basis of the Janssen
Diagnostic CellSearch System. Laboratory personnel were blinded to the
ordering of samples and to all clinical information.
Statistical Analysis
Methylation data of each gene were log transformed after a small
constant (0.1) was added to all values to account for zeros in the data. The
inter- and intrabatch variation was evaluated using the coefficient of
variation (CV) for all 10 genes and the CMI. Genes were selected for
inclusion in the final analysis on the basis of CV, without reference to
performance. Median progression-free survival (PFS) and overall survival
(OS) with 95% CIs were estimated using the Kaplan-Meier method.
Survival distributions were compared between patients with high and low
CMIs at week 4 using the Gehan test, which gives more weight to early
differences. Landmark analyses of PFS and OS were performed with the
a priori defined time set at 4 weeks after treatment initiation. Patients who
experienced disease progression or death before week 4 were excluded.
Hazard ratios (HRs) and 95% CIs were estimated using the Cox pro-
portional hazards models, controlling for age, ethnicity, prior therapy,
phenotype, and disease burden. For classification of subjects into risk
groups by CMI, a cut point was determined using an outcome-oriented
approach for PFS and OSwith a selection procedure that was based on the
maximal log-rank statistic.17 A two-fold cross-validation approach18 was
applied to confirm the significance of the cut point and to obtain almost
unbiased estimates of the HR. The variability of the estimated HR using
this approach was assessed by repeating the cross-validation 500 times
with different choices of 1:1 random splits of the original data set.
Likelihood ratio tests were used in nested Cox models to assess the
added value of each biomarker (CMI or CTCs at baseline or week 4) in
predicting PFS and OS beyond established risk factors. The proportionality
assumption was met by graphically assessing plots of log (2log [survival])
versus log of survival time. Because of the limited sample size, interaction
terms (eg, potentially different effects of the biomarkers on outcomes by
hormone receptor status) were examined using the Wald test but were not
retained in the final models. The prognostic impact of the CMI according
to each biologic subtype (hormone receptor and human epidermal growth
factor receptor 2 status) was explored. Baseline and week 4 CMI, as well as
change from baseline, were also evaluated as continuous markers with
respect to outcomes. Disease status at first restaging was classified into one
of three categories, progressive disease (PD), stable disease, or responsive
disease (partial response/complete response) determined at approximately
8 to 12 weeks after the treatment started. The nonparametric Jonckheere-
Terpstra trend test was used to assess whether week 4 CMI levels or re-
duction at week 4 from baseline differed among ordered disease status at
first restaging. Association analyses of PD at first restaging (PD v non-PD)
were performed using logistic regression.
All tests were two-sided and considered statistically significant at
P, .05 and were performed using SAS 9.4 (SAS Institute, Cary, NC) and
R version 3.1.0 (available at http://www.r-project.org).
RESULTS
A total of 182 women were enrolled in the study. Serum samples
from the first 33 patients (taken before the start of sample col-
lection for the CTC assay) were used for analytical validation of the
cMethDNA assay,7 leaving 149 women with available samples for
this study. Of the 149 women, eight were excluded subsequently
(Appendix Fig A2), resulting in an analytic population of 141.
Table 1 describes the patient characteristics of our analytic pop-
ulation. Serumwas available to evaluate the CMI in duplicates at two
time points (at baseline and at week 4) in 129 women, and at a third
time point for 112 of the 129 women. Information on CTCs was
available at baseline and at week 4 for 96 women. Median follow-up
for the cohort was 19.5 months (range, 0.8 to 86.3 months).
The MI at baseline was calculated for all 10 genes (Appendix
Fig A3), and the results were highly correlated with one another
(Appendix Table A1, online only). Four of the genes (COL6A2,
ARHGEF7, TMEFF2, and GXP7) were excluded from analyses
because of CVs . 20%. The six genes included were AKR1B1,
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HOXB4, RASGRF2, RASSF1, HIST1H3C, and TM6SF1. The inter-
and intrabatch CVs for any of the genes were, 18% (the majority
having a CV , 10%), which is considered acceptable.19 The inter-
and intrabatch CVs for the CMI of the six genes were , 2.5%.
Landmark analyses were performed on the basis of week 4.
A cut point of 9 for PFS and 21 for OS were the values selected for
the week 4 CMI that maximized the log-rank statistic. One patient
who had PD before the landmark time point was excluded. In the
multivariable models described in Table 2, patients with a high
CMI at week 4 had a significantly worse PFS (HR, 1.79; 95% CI,
1.23 to 2.60; P = .002) after adjusting for age, ethnicity, prior
therapy, tumor phenotype, and disease burden. Similar results for
OS (HR, 1.75; 95% CI, 1.21 to 2.54; P = .003) are illustrated in
Table 3.
The median PFS among women in the high versus low CMI
group was 2.1 months (95% CI, 1.7 to 3.2 months) versus
5.8 months (95%, CI 4.7 to 7.4 months), respectively (Fig 1A).
The median OS was almost a year shorter for women in the high
(12.3months; 95%CI, 8.4 to 16.5months) versus low (21.7months;
95% CI, 19.3 to 28.3 months) CMI group (Fig 1B). Baseline CMI,
modeled continuously, was not associated with PFS but was as-
sociated with OS in multivariate analyses (Appendix Fig A4). The
prognostic effect of the week 4 CMI was consistent across different
biologic subtypes; however, the sample size of some subtypes was
small (Appendix Table A2). Sensitivity analyses for factors such as
body mass index, study site, and the 10-gene panel did not alter the
observed estimates. To evaluate the robustness of the two-fold cross-
validation approach, we repeated the two-fold cross-validation
procedure 500 times to allow for different choices of the 1:1 random
split of the original data set and calculated the corresponding HR.
The mean HR for PFS was 1.95 (variance, 0.048), and the mean HR
for OS was 1.87 (variance, 0.023), which is considered stable and
within the range of our original results.
The association between CMI levels at baseline, at week 4, and
at first restaging and disease status as early as first restaging, which
was most often at week 12, was also examined. Figure 2A illustrates
the distributions of log CMI levels at baseline, at week 4, and at first
restaging by disease status. A significant trend was observed
between an increasing CMI at week 4 and less responsive disease
at first restaging (P for trend , .001, Jonckheere-Terpstra test).
The median CMI at week 4 was highest in women with PD, lowest
in women with responsive disease (partial response/complete re-
sponse), and intermediate in women with stable disease at first
restaging.
Next, the effect on disease status of a change in CMI levels
from baseline to week 4 was examined. Women with responsive
(P , .001) or stable (P , .001) disease were more likely to have
a reduction in median levels of the CMI from baseline to week 4
(Fig 2A). As illustrated in Tables 2 and 4, a change in log CMI
from baseline to week 4 was associated with worse PFS (HR, 1.21;
95% CI, 1.09 to 1.34; P , .001) and PD at first restaging (OR,
1.55; 95% CI, 1.20 to 2.01; P, .001). When a change in the CMI
was modeled as a binary variable in multivariable analyses, an
increase in the CMI at week 4 was associated with a worse PFS
(HR, 2.18; 95% CI, 1.40 to 3.41; P, .001) and a 4.6-fold increase
in the risk of PD at first restaging (OR, 4.58; 95% CI, 1.82 to
11.60; P = .001) compared with a reduction or no change in the
CMI. In either case, adjusting for the baseline CMI did not alter
the point estimates.
In this study, we were also able to evaluate CTCs at baseline
and at week 4 in 96 women. The distribution of CTC values is
illustrated in Appendix Figure A5. As was the case with the CMI,
week 4 CTCs $ 5 cells/7.5 mL were significantly associated with
worse PFS (HR, 1.46; 95% CI, 1.02 to 2.10; P = .04) and OS
(HR, 2.24; 95% CI, 1.54 to 3.26; P , .001). The median OS
for$ 5 cells/7.5 mLwas 8.1 months (95% CI, 4.9 to 18.8 months)
and 20.8 months (95% CI, 17.5 to 26.6 months) for, 5 cells/7.5 mL.
As was the case with the CMI, CTCs at week 4 were reduced in
women with responsive disease (P = .0001; Fig 2B). However, in
contrast to CMI, CTC levels were not significantly different by
disease status at first restaging (P for trend = .457; Fig 2B). The
CMI was more sensitive (78%) in identifying high-risk (pro-
gressive) disease than were CTCs (30%). A change in CTCs
modeled either as a continuous marker (Appendix Fig A6) or as
a binary marker (increase or reduction v no change from baseline;
OR, 2.23; 95% CI, 0.77 to 2.47) was not significantly associated
with PD at first restaging in multivariable analyses.
Finally, as an exploratory analysis, we examined the prog-
nostic significance of the CMI and CTCs in 96 women in whom
both markers had been measured (Appendix Table A3). Likeli-
hood ratio tests suggest that the addition of either the week 4 CMI
or CTCs significantly improved the ability of a model of estab-
lished risk factors to predict PFS (P , .001and P = .038 for the




Age, years, median (range) 56 (29-84)







BMI,‡ kg/m2, median (range) 26.0 (18-44)
Tumor phenotype of initial diagnosis
ER positive/PR positive/HER2 negative§ 85 (60)
HER2 positive (any ER) 29 (21)
Triple negative 27 (19)
Disease burden
Visceral only (liver, lung, brain) 23 (16)




Chemotherapy only 33 (23)
Hormone therapy only 29 (21)
Chemotherapy and hormonal therapy 42 (30)
Elevated CTC level ($ 5) 71 (50)
Progression-free survival, months, median (95% CI) 4.4 (3.3 to 5.8)
NOTE. Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CTC, circulating tumor cell; ECOG,
Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human
epidermal growth factor receptor 2; PR, progesterone receptor.
*Including one Asian.
†On the basis of self-report data from baseline questionnaire.
‡Excluding 12 patients who did not have baseline height or weight information
available.
§Including eight subjects with unknown HER2 status.
║In themetastatic setting (some subjectsmay receive adjuvant chemotherapy).
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CMI and CTCs, respectively) and OS (P = .043 and P = .007 for
the CMI and CTCs, respectively). Furthermore, the CMI at week
4 seemed to be a significant predictor of PFS and improved the
prediction of the base model even in the presence of CTCs
(P = .004). In separate models, a change in the CMI in the base
model improved PFS (P = .002), but a change in CTC level did
not. The improvement with the change in the CMI occurred
even in the presence of CTCs (P = .007). The addition of
a change in CTC level or in the CMI did not significantly
improve the model fit for OS.
DISCUSSION
To our knowledge, this is the first study to demonstrate the promise
of early changes in the level of circulating cell-free tumor-specific
DNA methylation for clinical application in patients with MBC.
Our results suggest that CMI levels of a novel six-gene panel
measured 4 weeks after the initiation of a new therapy and a novel
quantitative assay known as cMethDNA have clinical usefulness as
a predictor of survival outcomes in women with MBC. A high CMI
Table 2. Association of CMI Levels and Prognostic Factors With Progression-Free Survival in Women with Metastatic Breast Cancer
Variable
Univariate Analysis Multivariable Analysis
No. Events HR (95% CI)* P No. Events HR (95% CI)* P
Age, years 138 0.97 (0.96 to 0.99) , .001 126 0.97 (0.96 to 0.99) .003
Ethnicity, black v white 138 1.22 (0.78 to 1.92) .79 126 1.32 (0.81 to 2.8) .270
Prior therapy, yes v no 138 1.21 (0.82 to 1.78) .331 126 0.91 (0.59 to 1.39) .649
Disease burden, visceral v nonvisceral 138 0.96 (0.68 to 1.37) .839 126 1.02 (0.69 to 1.50) .915
Phenotype 138 126
HER2 positive (any ER) v ER positive/PR positive/
HER2 negative
1.31 (0.85 to 2.01) .219 1.09 (0.69 to 1.72) .727
Triple negative v ER positive/PR positive/HER2 negative 0.92 (0.59 to 1.44) .702 0.75 (0.44 to 1.27) .280
HER2 positive (any ER) v triple negative 1.43 (0.83 to 2.47) .202 1.45 (0.79 to 2.66) .231
Log week 4 CMI† (continuous) 126 1.15 (1.05 to 1.25) .002 126 1.13 (1.04 to 1.23) .006
Week 4 CMI, high‡ v low (with cross-validation) 126 1.76 (1.23 to 2.52) .002 126 1.79 (1.23 to 2.60) .002
Log CMI change from baseline to week 4† (continuous) 126 1.19 (1.07 to 1.32) .001 126 1.21 (1.09 to 1.34) , .001
NOTE. Progression-free survival was calculated from the date treatment started to the date of first documentation of progressive disease as determined by standard
Response Evaluation Criteria in Solid Tumors, clinical deterioration, or rising tumor markers in the situation in which imagingwas not performed, or the time of death from
any cause, whichever came first. Those who remained alive without progressive disease were censored at the time of their last tumor assessment.
Abbreviations: CMI, cumulative methylation index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone
receptor.
*HRs and 95% CIs were estimated and P values obtained using Cox proportional hazards models with the multivariable analysis adjusting for age, ethnicity, prior
therapy, phenotype, and disease burden. For dichotomized week 4 CMI, HR was obtained using a stratified Cox regression model.
†Continuous CMI (log week 4 CMI, log CMI change from baseline to week 4) was assessed using a separate multivariable model adjusting for age, ethnicity, prior
therapy, phenotype, and disease burden.
‡High in this analysis is based on a week 4 CMI . 9. The remaining individuals were classified as low.
Table 3. Association of CMI Levels and Prognostic Factors With Overall Survival in Women With Metastatic Breast Cancer
Variable
Univariate Analysis Multivariable Analysis
No. Events HR (95% CI)* P No. Events HR (95% CI)* P
Age, years 133 0.99 (0.97 to 1.00) .115 121 0.99 (0.98 to 1.01) .441
Ethnicity, black v white 133 1.75 (1.10 to 2.77) .018 121 1.89 (1.11 to 3.22) .020
Prior therapy, yes v no 133 1.05 (0.71 to 1.55) .813 121 1.21 (0.78 to 1.88) .393
Disease burden, visceral v nonvisceral 133 1.23 (0.86 to 1.76) .258 121 1.16 (0.79 to 1.72) .450
Phenotype 133 121
HER2 positive (any ER) v ER positive/PR positive/
HER2 negative
1.00 (0.64 to 1.57) .987 1.01 (0.62 to 1.65) .964
Triple negative v ER positive/PR positive/HER2 negative 1.60 (1.02 to 2.51) .041 1.76 (1.05 to 2.95) .032
HER2 positive (any ER) v triple negative 0.63 (0.36 to 1.09) .100 0.57 (0.31 to 1.06) .078
Log week 4 CMI† (continuous) 121 1.14 (1.04 to 1.25) .004 121 1.17 (1.06 to 1.28) .001
Week 4 CMI, high‡ v low (with cross-validation) 121 1.70 (1.18 to 2.45) .005 121 1.75 (1.21 to 2.54) .003
Log CMI change from baseline to week 4† (continuous) 121 1.08 (0.98 to 1.20) .104 121 1.08 (0.98 to 1.20) .123
NOTE. Overall survival was defined as the date treatment started to the date of death from any cause. Those who remained alive were censored at the date last known
to be alive.
Abbreviations: CMI, cumulative methylation index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.
*Cox proportional hazard models and stratified Cox regression were used to estimate HRs and 95% CIs and P values. The multivariable analysis was adjusted for
age, ethnicity, prior therapy, phenotype, and disease burden. HRs and 95% CIs were estimated and P values obtained using Cox proportional hazards models with the
multivariable analysis adjusting for age, ethnicity, prior therapy, phenotype, and disease burden. For dichotomized week 4 CMI, HR was obtained using a stratified Cox
regression model.
†Continuous CMI (log week 4 CMI, log CMI change from baseline to week 4) was assessed using a separate multivariable model adjusting for age, ethnicity, prior
therapy, phenotype, and disease burden.
‡High in this analysis is based on a week 4 CMI .21. The remaining individuals were classified as low.
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level at week 4 was consistently associated with PFS and OS, as well
as PD, as early as first restaging. Furthermore, a change in the CMI
within 4 weeks of initiating therapy tracked with PFS and disease
response as early as first restaging, supporting the potential prog-
nostic usefulness of measuring CMI levels within weeks of initiating
a new therapy. Last, both the CMI at week 4 and a change in the CMI
added to the ability of established risk factors, including CTCs, to
predict PFS.
The six-gene panel examined in this study is based on the
results of a DNA methylation array conducted in breast tumors
and sera for patients with both estrogen receptor–positive and
estrogen receptor–negative breast cancer.7 Five of the six genes in
the six-gene panel were identified by our group as methylated in
breast cancer.7 Two genes with some degree of commonality in
functionwere RASGRF1, a RAS guanosine triphosphate hydrolase
with nucleotide exchange function,20 and RASSF1, a methylation
marker common to many cancers that encodes a protein similar
to RAS effector proteins.21 Among the four other novel genes,
HIST1H3C interacts with linker DNA between nucleosomes and
functions in the compaction of chromatin into higher-order
structures,22 the AKR1B1 gene encodes a member of the aldo/keto
reductase superfamily and catalyzes the reduction of a number of
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Fig 1. Kaplan-Meier curves of (A) progression-
free survival and (B) overall survival by CMI at
week 4 for women with metastatic breast can-
cer. Landmark analysis at week 4 excluded pa-
tients encountering events before blood draw at
week 4. A horizontal line indicates median sur-
vival times. Gehan tests were stratified by
subset resulting from random split of the data
with the two-fold cross-validation. CMI, cumu-
lative methylation index; HR, hazard ratio.
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aldehydes,23 and HOXB4 encodes a transcription factor involved
in development and, as with many members of the HOX gene
family, is regulated by methylation of dense C-phosphate-G
islands.24 There is no literature regarding the function of the
newly discovered TM6SF1.7 The cMethDNA assay can measure
methylation levels in gene loci coamplified from one 300-mL
aliquot of serum. The cMethDNA assay is calibrated against a low
fixed physiologic level of recombinant gene-specific reference DNA
that is copurified and coamplified with target methylated DNA.7
A few other studies have evaluated the relationship between
cell-free tumor DNA in plasma and serum and disease outcome
in patients with breast cancer.12-15,25-28 Those studies did not
quantify the level of methylation either as a categorical or as
a continuous measure, as we report in this article. Most of the
studies were based in a single institution, measured a limited
number of candidate genes at a single time point, had a small
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Fig 2. Association of disease status at first restaging with (A) CMI and (B) CTCs across three time points. The length of the box is the interquartile range and represents
the middle 50% of the data. The horizontal line inside the box shows the median. The lower and upper edges of the box represent the 25th and 75th percentiles,
respectively. The vertical dashed lines extend from the box to the upper and lower 1.5 interquartile values from the upper and lower edges. Jonckheere-Terpstra test for
trend in change from baseline among ordered disease status at first restaging. *Significant difference (P , .001) at the given time point compared with baseline using
Wilcoxon signed rank test. Natural log transformed CMI and CTC data were graphed and the y-axes were formatted with back-transformation values. CMI, cumulative
methylation index; CTCs, circulating tumor cells; PD, progressive disease; PR/CR, partial response/complete response; SD, stable disease.
Table 4. Association of CMI Levels and Prognostic Factors With Progressive Disease at First Restaging (N = 134)
Variable
Univariate Analysis Multivariable Analysis
OR (95% CI)* P OR (95% CI)* P
Age, years 0.98 (0.95 to 1.01) .128 0.99 (0.95 to 1.02) .454
Ethnicity, black v white 1.61 (0.64 to 4.02) .313 2.13 (0.72 to 6.30) .171
Prior therapy, yes v no 1.12 (0.51 to 2.49) .777 1.05 (0.41 to 2.67) .920
Disease burden, visceral v nonvisceral 0.96 (0.46 to 2.01) .920 0.90 (0.38– 2.10) .805
Phenotype
HER2 positive v ER positive/PR positive/HER2 negative 1.06 (0.45 to 2.51) .897 1.35 (0.49 to 3.74) .567
Triple negative v ER positive/PR positive/HER2 negative 1.00 (0.40 to 2.50) . .999 0.56 (0.18 to 1.78) .325
HER2 positive (any ER) v triple negative 1.06 (0.36 to 3.15) .918 2.40 (0.67 to 8.64) .180
Log week4 CMI (continuous) 1.32 (1.09 to 1.62) .006 1.32 (1.08 to 1.62) .006
Log CMI change from baseline to week 4 (continuous) 1.52 (1.18 to 1.96) .001 1.55 (1.20 to 2.01) , .001
NOTE. Disease status at first restaging was classified into two categories: progressive disease v stable disease or responsive disease (partial response/complete
response) after new treatment initiated.
Abbreviations: CMI, cumulative methylation index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; PR, progsterone receptor.
*ORs and 95% CIs were estimated and P values obtained using logistic regression models with the multivariable analysis adjusting for age, ethnicity, prior therapy,
disease burden, and phenotype. Continuous CMI (log week 4 CMI, log CMI change from baseline to week 4) was assessed using a separate multivariable model
adjusting for age, ethnicity, prior therapy, phenotype, and disease burden.
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In our comparison of the CMIwith CTCs, a clinically available
biomarker for risk stratification in patients with breast cancer, the
CMI and CTCs at week 4 seem to be complementary as prognostic
markers, but both the CMI and a change in the CMI were stronger
predictors of PFS when contrasted directly with CTCs.29,30 When
predicting treatment response at first restaging, CTCs were more
specific (85%) in identifying low-risk (stable or responsive) disease
compared with the CMI (51%), whereas the CMI was more
sensitive (78%) in identifying high-risk (progressive) disease than
were CTCs (30%). Of interest, numeric changes in CTC level
between baseline and week 4 were not associated with treatment
response. Women with a high CTC level at both baseline and week
4 compared with those with a low CTC level had a worse PFS and
OS; this finding is consistent with a recent clinical trial in MBC in
which change in treatment guided by CTCs did not influence
disease outcome.30 Although monitoring for the change in the
CMI for treatment response has prognostic usefulness, its clinical
usefulness in influencing changes in therapy must now be eval-
uated formally in randomized clinical trials. Furthermore, whether
there is meaningful risk reclassification of patients with the ad-
dition of the CMI is worth careful assessment in future larger
validation studies.
To our knowledge, this is the first prospective study to
demonstrate the potential clinical usefulness of measures of se-
rummethylation to inform clinical care in breast cancer. The CMI
of a panel of six genes and change in CMI levels were independent
predictors of survival outcomes. Limitations of the study include
the lack of central adjudication for outcomes such as PD, al-
though these results seem to align with death, a less subjective
outcome. Other limitations include the lack of blood samples
before week 4 and the modest sample size. Our findings must be
validated to determine the clinical usefulness of the cMethDNA
assay for specific treatments and tumor phenotypes in patients
with metastatic disease and early-stage breast cancer.
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Disease assessment (clinical examination and imaging studies)
Fig A1. TBCRC-005 study schema. For this study, we had duplicate serum samples from 141women at baseline. In addition, for 129 of the 141women, we had duplicate
measures at a second time point, and for 112 of the 129 women, duplicate measures at a third time point.
Patients enrolled in TBCRC 005
between January 2007 and June 2009
(N = 182) 
cMethDNA assay performed
(n = 149) + 5% QCs (n = 72)
Patient were excluded because they did not get treated
(n = 3) or because there was not enough sample
for duplicate assays (n = 2) or because all 10 genes
were not measured in duplicate (n = 3)
Samples from women used for
analytical validation (n = 33)
Analytic population
(n = 141)
Fig A2. Flow chart describing study population. Patients were enrolled from the following seven cancer centers: Johns Hopkins Sidney Kimmel Cancer Center,
Baltimore, MD; University of Alabama at Birmingham, Birmingham, AL; Indiana University, Bloomington, IN; University of Chicago, Chicago, IL; Dana-Farber Cancer
Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; and Mayo Clinic, Rochester, MN. QCs, quality control samples.
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HR 95% 95%LCL UCL
Fig A4. Forest plot of the association of CMI and CTCs as a continuous marker with both PFS and OS. Baseline and week 4 CTCs and CMI modeled as a continuous
marker and both PFS and OS. All markers were treated as continuous variables and log transformed. The bars represent 95% CIs. The size of the box is indicative of the
precision of the point estimate. CMI, cumulative methylation index; CTCs, circulating tumor cells; HR, hazard ratio; LCL, lower confidence limit; OS, overall survival; PFS,













AKR1B1 COL6A2 HOXB4 RASFGR2 RASSF1
Gene
HIST1H3C GPX7 ARHGEF7 TMEFF2 TM6SF1
No. of values 141 141 141 141 141 141 141 141 141 141
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
25% Percentile 0.0 0.0 0.0 0.0 0.0330 0.0 0.0010 0.0 0.0 0.0
Median 8.178 1.331 3.670 3.274 9.531 3.632 0.0040 0.0 0.0 0.7330
75% Percentile 26.60 6.633 39.27 34.43 40.83 33.64 3.616 5.478 7.905 31.59
Maximum 98.06 81.08 97.52 97.11 96.81 99.08 94.45 94.19 98.79 97.05
Fig A3. Scatter plot summarizing the MI for each of the 10 genes evaluated. MI = [(No. methylated copies)/(No. methylated + gene standard copies)]3 100. MI for each
sample was averaged across duplicates. MI, methylation index.
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0.8 1 1.2 1.4 1.6 1.8 2
OR 95% 95%LCL UCL
Fig A6. Forest plot of the association of CMI and CTCs as a continuous marker with
disease status at first restaging. All markers were treated as continuous variables and were
log transformed. The bars represent 95%CIs. The size of the box is indicative of precision of
the point estimate. CMI, cumulative methylation index; CTCs, circulating tumor cells; LCL,
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Fig A5. Baseline and week 4 distributions of CTCs. CTCs, circulating tumor cells.
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Table A1. Correlation Among Baseline Methylation of All 10 Genes With Each Other
Gene
Spearman Correlation Coefficients and P Values* (N = 141)
AKR1B1 COL6A2 HOXB4 RASFGR2 RASSF1 HIST1H3C GPX7 ARHGEF7 TMEFF2 TM6SF1
AKR1B1 1.0000 0.6136 0.3987 0.6914 0.5941 0.2966 0.4978 0.5428 0.6150 0.5833
, .0001 , .0001 , .0001 , .0001 , .001 , .0001 , .0001 , .0001 , .0001
COL6A2 0.6136 1.0000 0.3856 0.6844 0.5797 0.2385 0.5008 0.5916 0.5681 0.6227
, .0001 , .0001 , .0001 , .0001 .0044 , .0001 , .0001 , .0001 , .0001
HOXB4 0.3987 0.3856 1.0000 0.4319 0.3392 0.2153 0.3937 0.4571 0.3271 0.4527
, .0001 , .0001 , .0001 , .0001 .0103 , .0001 , .0001 , .0001 , .0001
RASFGR2 0.6914 0.6844 0.4319 1.0000 0.6081 0.2334 0.5467 0.6868 0.6715 0.7113
, .0001 , .0001 , .0001 , .0001 .0054 , .0001 , .0001 , .0001 , .0001
RASSF1A 0.5941 0.5797 0.3392 0.6081 1.0000 0.2508 0.5062 0.4422 0.5731 0.5251
, .0001 , .0001 , .0001 , .0001 .0027 , .0001 , .0001 , .0001 , .0001
HIST1H3C 0.2966 0.2385 0.2153 0.2334 0.2508 1.0000 0.2107 0.2909 0.2786 0.2373
0.0004 0.0044 0.0103 0.0054 0.0027 0.0121 0.0005 0.0008 0.0046
GPX7 0.4978 0.5008 0.3937 0.5467 0.5062 0.2107 1.0000 0.5028 0.4490 0.5346
, .0001 , .0001 , .0001 , .0001 , .0001 .0121 , .0001 , .0001 , .0001
ARHGEF7 0.5428 0.5916 0.4571 0.6868 0.4422 0.2909 0.5028 1.0000 0.5297 0.7450
, .0001 , .0001 , .0001 , .0001 , .0001 , .001 , .0001 , .0001 , .0001
TMEFF2 0.6150 0.5681 0.3271 0.6715 0.5731 0.2786 0.4490 0.5297 1.0000 0.6081
, .0001 , .0001 , .0001 , .0001 , .0001 , .001 , .0001 , .0001 , .0001
TM6SF1 0.5833 0.6227 0.4527 0.7113 0.5251 0.2373 0.5346 0.7450 0.6081 1.0000
, .0001 , .0001 , .0001 , .0001 , .0001 .0046 , .0001 , .0001 , .0001
*P value: probability . |r| under H0: r = 0.
Table A2. Association of Week 4 CMI by Hormone Receptor and HER2 Status in Univariate Analysis
Subgroup
PFS OS
n HR (95% CI) P n HR (95% CI) P
Week 4 CMI, high v low
Hormone receptor positive 96 2.28 (1.48 to 3.50) , .001 96 1.75 (1.15 to 2.67) .009
Hormone receptor negative 32 1.69 (0.80 to 3.57) .169 33 2.36 (1.12 to 4.98) .024
HER2 positive 28 1.89 (0.85 to 4.21) .121 28 4.05 (1.58 to 10.4) .004
HER2 negative 92 2.05 (1.33 to 3.16) .001 93 1.50 (0.98 to 2.28) .061
Abbreviations: CMI, cumulative methylation index; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; PFS, progression-free
survival.
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Table A3. Assessment of the Added Value of CMI and CTCs in Predicting PFS and OS in Women With Metastatic Breast Cancer
Model (n = 96)
PFS OS
x2 Statistic* P x2 Statistic* P
A
Base model — — — —
Base model + baseline CMI 0.01 .920 6.518 .011
Base model + baseline CMI + week 4 CMI 13.649 , .001 4.114 .043
Base model + baseline CMI + week 4 CMI + baseline CTCs 0.860 .313 2.657 .103
Basemodel + baseline CMI +week 4 CMI + baseline CTCs +
week 4 CTCs
1.397 .237 3.329 .068
B
Base model — — — —
Base model + baseline CTCs 1.258 .262 6.017 .014
Base model + baseline CTCs + week 4 CTCs 4.298 .038 7.246 .007
Base model + baseline CTCs + week 4 CTCs + baseline CMI 1.853 .173 0.579 .447
Base model + baseline CTCs + week 4 CTCs + baseline CMI
+ week 4 CMI
8.507 .004 2.776 .096
C
Base model — — — —
Base model + change in CMI 9.547 .002 0.418 .518
Base model + change in CMI + change in CTCs 0.017 .896 0.004 .950
D
Base model — — — —
Base model + change in CTCs 2.231 .135 0.076 .783
Base model + change in CTCs + change in CMI 7.333 .007 0.346 .556
NOTE. Base model includes age, ethnicity, prior therapy, phenotype, and disease burden.
Abbreviations: CMI, cumulative methylation index; CTCs, circulating tumor cells; OS, overall survival; PFS, progression-free survival.
*Two times the difference of the log likelihood between nested models has a x2 distribution with one degree of freedom.
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